Pioneering a Transformative Era in Autoimmunity through B-Cell Depletion & Advancing Precision Therapies to Reprogram the Immune System to Move Beyond Standard Immunosuppression
The era of blanket immunosuppression is ending. The immune resetting revolution has arrived, and it’s moving rapidly. As the market grows, companies have the next two years to establish themselves as industry titans before this space becomes saturated. B-cell depletion therapies have paved the way, but the question remains: what’s next? Will you be among the leaders shaping the new era of immunology?
The Immune Resetting: B-Cell Mediated & Beyond Summit is the place to make your mark. Through extensive market research following breakthroughs in cell therapy, T-cell engagers, bispecifics, and next-generation monoclonal antibodies, as well as partnerships such as AbbVie’s acquisition of Capstan and investment trends driving the field, the program has been designed to position you at the center of it all.
During this pivotal moment, Immune Resetting: B-Cell Mediated & Beyond Summit will unite biopharma leaders, academic KOLs, and immunology innovators to accelerate progress. From discovery through clinical application, this is your opportunity to benchmark strategies, build partnerships, and take actionable insights back to your pipelines.
Join experts in an intimate forum built for candid conversation exploring how targeted interventions could recalibrate the immune system, delivering durable, transformative therapies for lupus, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, and beyond. The future of autoimmune care is being written, and you should be a part of it.
I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule, HB2198, for depletion of CD19/CD20 expressing B cells.
Steve Chapin, Senior Director – Preclinical Development, Hinge Bio
I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.
Jason Stadanlick, Principal Scientist, Cabaletta Bio
This is a rapidly evolving space, and the collaboration and information shared from companies was incredibly valuable at the TCEs for Autoimmune Disease Summit. I think we all believe we are competing but also each success will help the whole field out.
Tapan Maniar, Chief Medical Officer, Oblenio Bio
The Industry Momentum is Clear
Ouro Medicines, backed by GSK and founding investors Monograph Capital, just raised $120 million to advance T‑cell engager therapies aimed at depleting disease-driving B‑cells and resetting the immune system
Sanofi's recent $600 million acquisition of Dren Bio’s bispecific myeloid engager (DR0201) underscores big pharma’s rush into deep Bcell depletion and immune-reset strategies
A new BMS and Bain Capital spin-out just launched with $300 million in funding, licensing five immunology assets focused on lupus, psoriasis, atopic dermatitis, and other indications, all aimed at resetting immune pathways before saturation hits
Liberate Bio, developing in vivo CARM therapies to target myeloid-mediated immune reset, recently secured $31 million in seed funding. Another signal that innovative modalities are gaining traction fast
Explore the Full Event Guide
- 50+ Industry Attendees
- 18+ World-Class Speakers
- 5+ Modalities Covered
- 6+ Hours of Unrivaled Networking Opportunities
- 2 Deep-Dive Workshops
- The only industry forum dedicated to advancing curative therapies for autoimmune diseases through immune resetting
Attending Companies Include
Explore Related Events
Explore the Brand-New Agenda
Hear the latest industry breakthroughs in B-cell mechanistic understanding and gain exclusive modality and platform insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself as the go-to service provider of the rapidly progressing ‘Immune Resetting’ landscape to ensure your brand is at the heart of deals in this evolving space.
Join Biopharma Experts
Be part of the most critical conversations shaping the future of autoimmune therapy. Connect with like-minded experts across every stage of drug development, from discovery to clinical application, and dive into focused discussions on redefining immune reset.